Cover Image
Market Research Report
Product code 
1014748

Global Type 2 Diabetes Market 2021-2025

Published: | TechNavio (Infiniti Research Ltd.) | 120 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Type 2 Diabetes Market 2021-2025
Published: May 24, 2021
TechNavio (Infiniti Research Ltd.)
Content info: 120 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Technavio has been monitoring the type 2 diabetes market and it is poised to grow by $ 29.91 billion during 2021-2025, progressing at a CAGR of about 10% during the forecast period. Our report on the type 2 diabetes market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of diabetes and recent product approvals. In addition, rising prevalence of diabetes is anticipated to boost the growth of the market as well.

The type 2 diabetes market analysis includes the drug class segment and geographic landscape.

Technavio's type 2 diabetes market is segmented as below:

By Geography

  • North America
  • Europe
  • Asia
  • ROW

By Drug Class

  • Insulin
  • DPP-4 inhibitors
  • GLP-1 receptor agonists
  • SGLT-2 inhibitors
  • Others

This study identifies the rise in prevalence of obesity and changing lifestyles as one of the prime reasons driving the type 2 diabetes market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on type 2 diabetes market covers the following areas:

  • Type 2 diabetes market sizing
  • Type 2 diabetes market forecast
  • Type 2 diabetes market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading type 2 diabetes market vendors that include Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, and Takeda Pharmaceutical Co. Ltd. Also, the type 2 diabetes market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR70605

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Drug Class
    • Market segments
    • Comparison by Drug Class
    • Insulin - Market size and forecast 2020-2025
    • DPP-4 inhibitors - Market size and forecast 2020-2025
    • GLP-1 receptor agonists - Market size and forecast 2020-2025
    • SGLT-2 inhibitors - Market size and forecast 2020-2025
    • Others - Market size and forecast 2020-2025
    • Market opportunity by Drug Class
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Amgen Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Co. Ltd.
    • Eli Lilly and Co.
    • Merck and Co. Inc.
    • Novartis AG
    • Novo Nordisk AS
    • Sanofi SA
    • Takeda Pharmaceutical Co. Ltd.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ billion)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Other1 - Market share 2020-2025 (%)
  • 22: Comparison by Other1
  • 23: Insulin - Market size and forecast 2020-2025 ($ billion)
  • 24: Insulin - Year-over-year growth 2020-2025 (%)
  • 25: DPP-4 inhibitors - Market size and forecast 2020-2025 ($ billion)
  • 26: DPP-4 inhibitors - Year-over-year growth 2020-2025 (%)
  • 27: GLP-1 receptor agonists - Market size and forecast 2020-2025 ($ billion)
  • 28: GLP-1 receptor agonists - Year-over-year growth 2020-2025 (%)
  • 29: SGLT-2 inhibitors - Market size and forecast 2020-2025 ($ billion)
  • 30: SGLT-2 inhibitors - Year-over-year growth 2020-2025 (%)
  • 31: Others - Market size and forecast 2020-2025 ($ billion)
  • 32: Others - Year-over-year growth 2020-2025 (%)
  • 33: Market opportunity by Other1
  • 34: Customer landscape
  • 35: Market share by geography 2020-2025 (%)
  • 36: Geographic comparison
  • 37: North America - Market size and forecast 2020-2025 ($ billion)
  • 38: North America - Year-over-year growth 2020-2025 (%)
  • 39: Europe - Market size and forecast 2020-2025 ($ billion)
  • 40: Europe - Year-over-year growth 2020-2025 (%)
  • 41: Asia - Market size and forecast 2020-2025 ($ billion)
  • 42: Asia - Year-over-year growth 2020-2025 (%)
  • 43: ROW - Market size and forecast 2020-2025 ($ billion)
  • 44: ROW - Year-over-year growth 2020-2025 (%)
  • 45: Key leading countries
  • 46: Market opportunity by geography ($ billion)
  • 47: Impact of drivers and challenges
  • 48: Vendor landscape
  • 49: Landscape disruption
  • 50: Industry risks
  • 51: Vendors covered
  • 52: Market positioning of vendors
  • 53: Amgen Inc. - Overview
  • 54: Amgen Inc. - Business segments
  • 55: Amgen Inc. - Key offerings
  • 56: Amgen Inc. - Key customers
  • 57: Amgen Inc. - Segment focus
  • 58: AstraZeneca Plc - Overview
  • 59: AstraZeneca Plc - Product and service
  • 60: AstraZeneca Plc - Key offerings
  • 61: AstraZeneca Plc - Key customers
  • 62: AstraZeneca Plc - Segment focus
  • 63: Boehringer Ingelheim International GmbH - Overview
  • 64: Boehringer Ingelheim International GmbH - Business segments
  • 65: Boehringer Ingelheim International GmbH - Key offerings
  • 66: Boehringer Ingelheim International GmbH - Key customers
  • 67: Boehringer Ingelheim International GmbH - Segment focus
  • 68: Daiichi Sankyo Co. Ltd. - Overview
  • 69: Daiichi Sankyo Co. Ltd. - Business segments
  • 70: Daiichi Sankyo Co. Ltd. - Key offerings
  • 71: Daiichi Sankyo Co. Ltd. - Key customers
  • 72: Daiichi Sankyo Co. Ltd. - Segment focus
  • 73: Eli Lilly and Co. - Overview
  • 74: Eli Lilly and Co. - Business segments
  • 75: Eli Lilly and Co. - Key offerings
  • 76: Eli Lilly and Co. - Key customers
  • 77: Eli Lilly and Co. - Segment focus
  • 78: Merck and Co. Inc. - Overview
  • 79: Merck and Co. Inc. - Business segments
  • 80: Merck and Co. Inc. - Key offerings
  • 81: Merck and Co. Inc. - Key customers
  • 82: Merck and Co. Inc. - Segment focus
  • 83: Novartis AG - Overview
  • 84: Novartis AG - Business segments
  • 85: Novartis AG - Key offerings
  • 86: Novartis AG - Key customers
  • 87: Novartis AG - Segment focus
  • 88: Novo Nordisk AS - Overview
  • 89: Novo Nordisk AS - Business segments
  • 90: Novo Nordisk AS - Key offerings
  • 91: Novo Nordisk AS - Key customers
  • 92: Novo Nordisk AS - Segment focus
  • 93: Sanofi SA - Overview
  • 94: Sanofi SA - Business segments
  • 95: Sanofi SA - Key offerings
  • 96: Sanofi SA - Key customers
  • 97: Sanofi SA - Segment focus
  • 98: Takeda Pharmaceutical Co. Ltd. - Overview
  • 99: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 100: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 101: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 102: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 103: Currency conversion rates for US$
  • 104: Research Methodology
  • 105: Validation techniques employed for market sizing
  • 106: Information sources
  • 107: List of abbreviations